Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing

Abstract

Abnormal expression of microRNA (miR) is associated with the occurrence and progression of various types of cancers, including papillary thyroid carcinoma (PTC). In the present study, the aim was to explore miR-486-5p expression and its role in PTC, as well as to investigate the biological function of its potential target genes. The expression levels of miR-486-5p and its clinicopathological significance were examined in 507 PTC and 59 normal thyroid samples via The Cancer Genome Atlas (TCGA). Subsequently, the results were validated using data from Gene Expression Omnibus (GEO) and ArrayExpress. Receiver operating characteristic and summary receiver operating characteristic curves were used to assess the ability of miR-486-5p in distinguishing PTC from normal tissue. Furthermore, potential miR-486-5p mRNA targets were identified using 12 prediction tools and enrichment analysis was performed on the encoding genes using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. The expression levels of miR-486-5p were consistently downregulated in PTC compared with in normal tissue across datasets from TCGA, GEO (GSE40807, GSE62054 and GSE73182) and ArrayExpress (E-MTAB-736). The results also demonstrated that miR-486-5p expression was associated with cancer stage (P=0.003), pathologic lymph node (P=0.047), metastasis (P=0.042), neoplasm (P=0.012) and recurrence (P=0.016) in patients with PTC. In addition, low expression of miR-486-5p in patients with PTC was associated with a worse overall survival. A total of 80 miR-486-5p-related genes were observed from at least 9 of 12 prediction platforms, and these were involved in ‘hsa05200: Pathways in cancer’ and ‘hsa05206: MicroRNAs in cancer’. Finally, three hub genes, CRK like proto-oncogene, phosphatase and tensin homolog and tropomyosin 3, were identified as important candidates in tumorigenesis and progression of PTC. In conclusion, it may be hypothesized that miR-486-5p contributes towards PTC onset and progression, and may act as a clinical target. However, in vitro and in vivo experiments are required to validate the findings of the present study.

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer

“…It is already known that miR-146b, miR-21, miR-221, miR-222, miR-181b are dysregulated in PTC. These molecules showed potential as biomarkers in PTC tissue and plasma/serum studies [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. It was also demonstrated that downregulation of miR-181b inhibits proliferation and promotes apoptosis in thyroid cancer TPC1 cells, making this miRNA a possible target for PTC treatment [ 24 ].…”

Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome

“…In addition, patients with low miR-486-5p showed a shorter overall survival as compared patients with high miR-486-5p level. These data suggest that miR-486-5p is implicated in thyroid cancer initiation and progression [142]. FBN1 was identified as a direct target of miR-486-5p in PTC cells [143].…”

<p>LncRNA GATA6-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer via Repressing microRNA-543 to Up-Regulating RKIP</p>

“…Dysregulation of miRNAs may lead to malignant transformation of cells, and they also participate in regulating the malignancy of cancer cells. 27 – 31 miR-543 has been reported to be crucial regulator in tumors. For example, miR-543 enhances the migration, invasion, and EMT of esophageal cancer cells via targeting phospholipase A2 group IVA; 32 miR-543 is overexpressed in colorectal cancer tissues and cell lines, and high expression of miR-543 is associated with shorter overall survival time and disease-free survival time of the patients, and it promotes the proliferation and metastasis of cancer cells by targeting KLF4 .…”